0001474064-12-000030.txt : 20120209
0001474064-12-000030.hdr.sgml : 20120209
20120209170609
ACCESSION NUMBER: 0001474064-12-000030
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20120207
FILED AS OF DATE: 20120209
DATE AS OF CHANGE: 20120209
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Nader Francois
CENTRAL INDEX KEY: 0001365343
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-23272
FILM NUMBER: 12588266
MAIL ADDRESS:
STREET 1: 550 HILLS DRIVE
CITY: BEDMINSTER
STATE: NJ
ZIP: 07921
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: NPS PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0000890465
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 870439579
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 550 HILLS DRIVE
CITY: BEDMINSTER
STATE: NJ
ZIP: 07921
BUSINESS PHONE: (908) 450-5300
MAIL ADDRESS:
STREET 1: 550 HILLS DRIVE
CITY: BEDMINSTER
STATE: NJ
ZIP: 07921
4
1
edgar.xml
PRIMARY DOCUMENT
X0304
4
2012-02-07
0000890465
NPS PHARMACEUTICALS INC
NPSP
0001365343
Nader Francois
550 HILLS DRIVE
BEDMINSTER
NJ
07921
1
1
0
0
President, CEO and Director
Common Stock
2012-02-07
4
A
0
60900
0
A
60900
D
Common Stock
2012-02-07
4
A
0
60900
0
A
60900
D
Stock Option
8.21
2012-02-07
4
A
0
107700
0
A
2022-02-07
Common Stock
107700
107700
D
Restricted Stock Units awarded under the 2005 Omnibus Incentive Plan that will be settled in NPS Common Stock as follows: (i) one third will vest on the first anniversary of date of grant, one third on the second anniversary of date of grant, and one third on the third anniversary of date of grant.
Restricted Stock Units awarded under the 2005 Omnibus Incentive Plan that will be settled in NPS Common Stock as follows: one half will vest upon FDA approval of GATTEX, and one half will vest upon FDA approval of NATPARA, with no shares being able to be earned after 7/31/14.
Stock options granted under the 2005 Omnibus Incentive Plan. The options become exercisable based on the following vesting schedule: 25% on the first anniversary of the grant and 6.25% every three months thereafter.
/s/ Francois Nader, by Edward Stratemeier as Attorney-in-Fact
2012-02-09